Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

(2015) Peter Hillmen et al.   LANCET

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

(2014) G. Cartron et al.   BLOOD

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

(2014) Richard R. Furman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients

(2012) F. J. Beurskens et al.   JOURNAL OF IMMUNOLOGY

Monoclonal antibody (mAb)-based cancer therapy

(2012) Margaret A. Lindorfer et al.   OncoImmunology

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

(2010) S. J. Lemery et al.   CLINICAL CANCER RESEARCH

Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma

(2010) G. O. Negrea et al.   HAEMATOLOGICA

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

(2010) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects

(2010) David M. Goldenberg et al.   LEUKEMIA & LYMPHOMA

Rituximab in Chronic Lymphocytic Leukemia

(2010) Samantha M. Jaglowski et al.   SEMINARS IN HEMATOLOGY

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia

(2009) G. Aue et al.   HAEMATOLOGICA

Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results

(2009) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

(2008) D. M. Goldenberg et al.   BLOOD

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia

(2008) Claes Karlsson et al.   BRITISH JOURNAL OF HAEMATOLOGY